SCHEMBL5218132

SCHEMBL5218132

CC(=O)Nc1ccc(-n2cc(-c3cnc4ccccc4n3)cn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.59
▸ RAB9A P51151 5/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ TP53 P04637 1/20 0.59
▸ STAT1 P42224 1/20 0.59
▸ TDP1 Q9NUW8 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ MCL1 Q07820 1/20 0.56
▸ HTT P42858 2/20 0.50
▸ OGT O15294 2/20 0.48
▸ ATIC P31939 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ HSP90AB1 P08238 1/20 0.47
▸ KMT2A Q03164 8/20 0.44
▸ MEN1 O00255 6/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13715633 0.89 RAB9A (0.45) NPC1RAB9ASMN1; SMN2TP53STAT1
SCHEMBL5218811 0.88 RAB9A (0.68) NPC1RAB9ASMN1; SMN2TP53STAT1
SCHEMBL5220954 0.83 KMT2A (0.54) TP53OGTKDM4EKMT2AMEN1
SCHEMBL5219466 0.80 NPC1 (0.48) NPC1RAB9ASMN1; SMN2HTTKDM4E
SCHEMBL14381236 0.80 BCHE (0.63) NPC1RAB9ASMN1; SMN2KDM4EHSP90AA1
SCHEMBL5216495 0.80 GRM4 (0.54) NPC1RAB9ASMN1; SMN2KDM4EGAA
SCHEMBL5219136 0.77 NPC1 (0.50) NPC1RAB9ASMN1; SMN2POLBHTT
SCHEMBL5215574 0.77 GRM4 (0.56) NPC1RAB9ASMN1; SMN2HTTKDM4E
SCHEMBL5216714 0.77 MAPT (0.50) NPC1RAB9ASMN1; SMN2HTTKDM4E
SCHEMBL5216003 0.75 NPC1 (0.62) NPC1RAB9ASMN1; SMN2TP53STAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 — — EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 — — EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 — — US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 — — EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 — — WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885RAB9A 1352/4885SMN1; SMN2 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback